Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on December 23, 2021. The filing reports the entry into a material definitive agreement regarding an equity offering.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a potential capital raise:
- Maximum Aggregate Sales Price: Up to $150 million.
- Instrument: Common Stock, par value $0.001 per share.
- Sales Agent: Jefferies LLC.
- Commission Rate: 3.0% of gross proceeds.
Material Changes
The material change reported is the execution of an Open Market Sale Agreement (At-the-Market Offering). Under this agreement, the Company may issue and sell shares from time to time through Jefferies. The Company retains the right to suspend or terminate the agreement at any time and has no obligation to sell any shares.
Guidance, Outlook, and Risks
Management Commentary: The proceeds from the sale of shares, if any, are intended for general corporate purposes, though specific allocation is not detailed in this excerpt. The offering is subject to the Company's shelf registration statement on Form S-3.
Risks and Contingencies: The filing notes that sales will be made only if deemed lawful under applicable securities laws. The agreement is subject to customary representations, warranties, and indemnification rights.
Investor Verification Checklist
- Verify the actual volume of shares sold and proceeds received under this agreement in subsequent filings (e.g., 10-Q or 10-K).
- Confirm the impact of the 3.0% commission on net proceeds.
- Review the Company's cash position and burn rate to assess the necessity of this capital raise.
- Check for any subsequent termination or suspension of the Sale Agreement.